Skip to main content

    HC Wainwright & Co. cuts Neurosense Therapeutics (NRSN) rating to Neutral

    GNG Research Market News

    By GNG Research

    On November 2, 2026, HC Wainwright & Co. cut its Neurosense Therapeutics Ltd (NRSN) rating from Buy to Neutral.

    Among one firm active over the past 90 days, zero hold a bullish rating. Six analysts set consensus price targets as of October 30, 2026, with a mean of $98.30, a median of $103.02 and a range of $3.54 to $189.00.

    Consensus Q4 FY2026 EPS is -$3.67, with revenue at $0. The next earnings report is on March 29, 2027.